News &amp; Updates

An intervention that involves informational and reminder text messages, among others, is a feasible approach for managing elevated blood pressure (BP) in the emergency department (ED) setting, as reported in a study.

Interactive text messaging helps control blood pressure in ED

ICH, high NIHSS score predict mortality in stroke after reperfusion

Some acute ischaemic stroke patients treated with mechanical thrombectomy remain at risk of death despite successful reperfusion, a study reports. Among these patients, symptomatic intracranial haemorrhage (ICH) and high post-thrombectomy National Institutes of Health Stroke Scale (NIHSS) score strongly predict 90-day mortality.

ICH, high NIHSS score predict mortality in stroke after reperfusion

Hs-cTnI less accurate at diagnosing MI in patients with prior CABG

05 Mar 2022

High-sensitivity cardiac troponin I (hs-cTnI) loses diagnostic accuracy for myocardial infarction (MI) in patients who had undergone prior coronary artery bypass grafting (CABG), though it remains highly sensitive and specific, a new study has found.

Hs-cTnI less accurate at diagnosing MI in patients with prior CABG

05 Mar 2022

T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors

05 Mar 2022 by

A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.

T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors

05 Mar 2022

Original New Drug Application Approvals by US FDA (16 - 28 February 2022)

New drug applications approved by US FDA as of 16-28 February 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 28 February 2022)

Add-on electrostimulation of no benefit to paediatric cystic fibrosis patients

A resistance exercise-training program is enough to yield gains in muscle strength and functional capacity in paediatric cystic fibrosis (CF) patients with mild-to-moderate pulmonary impairment, a study has found. Meanwhile, the addition of neuromuscular electrical stimulation (NMES) does not appear to provide extra benefit.

Add-on electrostimulation of no benefit to paediatric cystic fibrosis patients

Wearable defibrillator helps avoid sudden cardiac death after surgery

02 Mar 2022 by

Wearable cardioverter defibrillators (WCD) can effectively protect cardiac surgery patients from sudden cardiac death (SCD), according to a recent study, noting that SCD risk was substantial within the first 3 months after the procedure.

Wearable defibrillator helps avoid sudden cardiac death after surgery

Continuity of care cuts ASCVD risk in newly diagnosed dyslipidaemic patients

Good continuity of care (COC) helps prevent atherosclerotic cardiovascular disease (ASCVD) in patients with newly diagnosed dyslipidaemia, a recent Korea study has found.

Continuity of care cuts ASCVD risk in newly diagnosed dyslipidaemic patients

Mucolytics, ICS/LABA combinations cut stroke risk among COPD patients with allied conditions

Patients with chronic obstructive pulmonary disease (COPD) and allied conditions are at heightened risk of stroke, but treatment with mucolytic agents and the combination of inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) may protect against the risk, as shown in a study.

Mucolytics, ICS/LABA combinations cut stroke risk among COPD patients with allied conditions